Business Wire

TEJ-KOHLI-FOUNDATION

21.2.2020 09:02:12 CET | Business Wire | Press release

Share
Tej Kohli Foundation Seeks to Incubate New Projects That Can Eliminate Corneal Blindness By 2035

The Tej Kohli Foundation is to establish a new incubator to provide seed and acceleration funding to projects with the potential to help eliminate corneal blindness worldwide. Funding, practical resources and intellectual capital will be available to both commercial and non-commercial projects that have a clear path to the prevention, treatment and cure of corneal blindness; with funding decisions based on the magnitude of the total impact that a project will likely have in poor and underserved communities worldwide by 2035, as well as the likelihood that a project will succeed.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200221005010/en/

The Tej Kohli Foundation continues to build its position as a multi-disciplinary global centre of focus for the development and advancement of an affordable, scalable and accessible ‘universal solution’ for preventing and eliminating corneal blindness. The World Health Organisation says that 90% of those affected by blindness and severe visual impairment live in the poorest countries in the world. Whilst approximately 75% of corneal disease is curable by corneal transplant, the costs of invasive surgery, and the many years of medicine needed to prevent rejection after surgery, makes this form of treatment entirely inaccessible to the majority of the people in the world who suffer from severe visual impairment or corneal blindness.

Tej Kohli co-founded the eponymous Foundation in 2005 alongside wife Wendy Kohli. He has previously spoken about funding life-changing corneal transplants in poor and underserved communities as being “like Schindler’s List, you do a few, then you just have to do more” (https://www.telegraph.co.uk/technology/2019/10/04/tej-kohli-indian-tech-billionaire-plans-turbocharge-britains/ ). In December 2019 the Tej Kohli Foundation announced that it had restored the sight of 5,736 blind people during the year (https://www.businesswire.com/news/home/20191219005417/en/5736-World%E2%80%99s-Poorest-People-Received-Gift-Sight ) and committed $14m of further funding to its Cornea Institute.

Tej Kohli is also an evangelist of the opportunities that can be derived from the chain reaction of technological progression and the impact that they can have on human life: https://www.spearswms.com/billionaire-philanthropist-tej-kohli-ai/ . The new Tej Kohli Foundation incubator hopes to back projects that can leverage this chain reaction of technological progression to develop and deliver new techniques and applications and game-changing innovations for improving access. The Foundation is seeking to incubate between one and three new projects initially, and welcomes funding applications from all fields of expertise. Projects must show that they can make a significant impact by 2035.

The Tej Kohli Foundation funded its first donor cornea implants at Niramaya Hospital in India in 2010. After funding thousands of corneal transplants, in 2015 the Tej Kohli Foundation substantially expanded its efforts to tackle corneal blindness in poor and underserved communities with the ambitious launch the Tej Kohli Cornea Institute in Hyderabad. Between January 2016 and November 2019 the Tej Kohli Cornea Institute welcomed more than 223,404 outpatients and completed more than 43,255 surgical procedures. The Tej Kohli Foundation has also pursued a ‘universal treatment’ for corneal blindness through its ‘Applied Research’ program, which is a longstanding scientific collaboration between researchers in Montreal Canada, and Moorfields Eye Hospital in the UK.

In January 2020 seed funding from the Tej Kohli Foundation was granted to two new research projects. The first project will focus on preventing corneal endothelial cell loss, which is usually permanent and is the leading reason for corneal transplantation worldwide. The second project will use novel drugs released by contact lenses to treat ocular surface pain and overcome the need for opioids when treating severe eye pain, which remains one of the unmet needs in Ophthalmology.

Eligible projects are invited to submit a 2-page project abstract as a PDF to: project2035@tejkohlifoundation.com . Submissions will be considered by the Tej Kohli Foundation on a case-by-case basis in direct collaboration with its global network of specialists.

Wendy Kohli, co-Founder of the Tej Kohli Foundation said:

“The YouTube channel of the Tej Kohli Foundation has many stories of individuals who have been cured of severe visual impairment or corneal blindness. But the overwhelming majority of those living needlessly with blindness still cannot afford or access treatment. It is only through major innovations borne from research, science, technology and enterprise that we can move toward a world where nobody is needlessly blind because of poverty.”

Tej Kohli, co-Founder of the Tej Kohli Foundation said:

“There are many innovations already in the pipeline that could one day offer affordable, scalable and accessible solutions for prevention and cure in the poor and underserved communities where corneal blindness is most pervasive. At the Tej Kohli Foundation we are interested in backing and funding new innovations and projects that will accelerate progress toward the goal of eliminating poverty-driven corneal blindness worldwide by 2035.”

About the Tej Kohli Foundation:

Website: http://www.tejkohlifoundation.com

YouTube: https://www.youtube.com/c/tejkohlifoundation

About Tej Kohli:

Profile: https://www.tejkohlifoundation.com/tej-kohli

Twitter: https://twitter.com/mrtejkohli

About Wendy Kohli:

Profile: https://www.tejkohlifoundation.com/wendy-kohli

Social Media:

https://www.facebook.com/TejKohliFoundation/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye